Statins and gastric cancer risk

Hepato-Gastroenterology

Volumn 58, Issue 107-108, 2011, Pages 1057-1061

  Shimoyama, Shouji ^a  

^a Settlement Clinic   (Japan)

Author keywords

Gastric cancer; Metaanalysis; Serum cholesterol; Statin; Upper gastrointestinal cancer

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CANCER INCIDENCE; CANCER RISK; DIGESTIVE SYSTEM CANCER; DRUG USE; HUMAN; PRIORITY JOURNAL; PUBLICATION; STOMACH CANCER; UPPER GASTROINTESTINAL TRACT;

CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK; STOMACH NEOPLASMS;

EID: 80051619008     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Walley T, Folino-Gallo P, Schwabe U, van Ganse E; EuroMedStat group: Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004; 328:385-386. (Pubitemid 38241189)
2. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B: Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992; 86:1046-1060.
3. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 2005; 352:2184-2192.
4. Khurana V, Bejjanki HR, Caldito G, Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007; 131:1282-1288.
5. Blais L, Desgagné A, LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160:2363-2368.
6. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D: Primary prevention of cardiovascular mortality and events with statin treatments: a network metaanalysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52:1769-1781.
7. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM: Statins and cancer risk: a meta-analysis. JAMA 2006; 295:74-80. (Pubitemid 43042692)
8. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford. I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group: Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
9. DerSimonian R, Laird N: Meta-analysis in Clinical Trials. Control Clin Trials 1986; 7:177-188.
10. Higgins JPT, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
11. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J; 4S Group: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-777. (Pubitemid 39165096)
12. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
13. Sato S, Ajiki W, Kobayashi T, Awata N; PCS Study Group: Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006; 16:201-206. (Pubitemid 44574685)
14. Heart Protection Study Collaborative Group: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial (IS-RCTN48489393). BMC Med 2005; 3:6.
15. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group: Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486.
16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
17. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
18. Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R: Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol 2007; 99:970-973.
19. Nakagawa T, Kobayashi T, Awata N, Sato S, Reiber JH, Nakajima H, Toyama YN, Hiraoka H, Kato O, Kirino M, Kobayashi T, Takeda Y, Yachiku K, Iida M, Itoh T, Shibata N: Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: final 5-year angiographic follow-up of the Prevention of Coronary Sclerosis (PCS) study. Int J Cardiol 2004; 97:107-114. (Pubitemid 39178531)
20. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
22. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133:393-402. (Pubitemid 47187349)
23. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98:1819-1825. (Pubitemid 46017933)
24. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM: The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100:134-139. (Pubitemid 351480564)
25. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 2003; 9:10-19.
26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
27. Newman CB, Szarek M, Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Demicco DA, Auster S, Fuller JH; Cards Investigators: The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res 2008; 5:177-183.
28. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ: The risk of cancer in users of statins. J Clin Oncol 2004; 22:2388-2394. (Pubitemid 41115396)
29. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators: Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets (TNT) study). Am J Cardiol 2007; 100:747-752. (Pubitemid 47271930)
30. Okamura T, Kadowaki T, Hayakawa T, Kita Y, Okayama A, Ueshima H; Nippon Data80 Research Group: What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 2003; 253:169-180. (Pubitemid 36197537)
31. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284:311-318. (Pubitemid 30469857)
32. Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK: Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19:81-83. (Pubitemid 32209788)
33. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT, Olsen JH: Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114:643-647. (Pubitemid 40349625)
34. Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635-637. (Pubitemid 38297203)
35. Browning DR, Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833-843. (Pubitemid 46175404)
36. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM: Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006; 24:4808-4817. (Pubitemid 46655612)
37. Available at: http://monographs.iarc.fr/ENG/Classification/index.php. Accessed July 20, 2009.